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Suppression of matrix metalloproteinase-2-mediated
cell invasion in U87MG, human glioma cells by
anti-microtubule agent: in vitro study
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Summary Because microtubules are important components of cell motility and intracellular transport, it is reasonable to propose that the
depolymerizing effect of an antimicrotubule agent, estramustine, on glioma microtubules would modulate cell invasiveness. To determine
whether matrix metalloproteinases, key factors in cell invasion, are affected by exposure to estramustine, a cell proliferation assay, a
zymogram, a collagenolysis assay and a haptoinvasion assay were used in this study. The zymogram revealed that an activated (62 kDa)
form of matrix metalloproteinase-2 diminished with increasing estramustine concentrations. The collagenolysis assay demonstrated
approximately 2.5- to 21-fold lower rates of enzymatic activity suppressed by estramustine in a dose-dependent manner at estramustine
concentrations of 1, 5, and 10gM, compared with the control group. On the haptoinvasion assay, no statistically significant difference was
seen in the 0.5 gM estramustine group, whereas 1-10 gM estramustine groups revealed significant suppression of invasion from 6 to 24 h in
a dose-dependent manner. The results suggest that estramustine suppresses the invasion of U87MG cells in vitro using the decreasing
available matrix metalloproteinase-2, an effect caused by the disassembly of microtubules. Suppression of the infiltrative capacity of
malignant glioma cells could be of significant value in the treatment of this disease.
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Malignant gliomas are highly invasive with a dismal prognosis
despite aggressive therapeutic interventions. Invasion is accompa-
nied by remodelling ofthe vasculature and the destruction ofadja-
cent normal brain tissue (Bernstein et al, 1991). The arrest of
tumour invasion in glioma is important because these tumours do
not metastasize to distant organs and can be regarded as alocalized
disease. The invasiveness ofgliomas depends on the disruption of
the neighbouring extracellular matrix and the penetration of
tumour cells into the adjacent normal brain structures.
Microtubules are one component of the microfilaments of the
cytoskeleton. Microtubules are composed of polymerized tubulin
dimers (Bohn et al, 1993), andplay various importantroles such as
the maintenance of the cell shape (Coomber, 1991; Cameron and
Rakic, 1994), and the formation of the mitotic spindle during the
M phase of the cell cycle (Dahllof et al, 1993). Microtubules also
contribute to cell motility (Maria et al, 1992; Rutberg and Wallin,
1993) and the intracellular transport of mRNA and proteins (Lin
and Forscher, 1993). Estramustine phosphate (EMP) is an anti-
microtubule agent that causes a partial disassembly of micro-
tubules (Hudes et al, 1992). This agent is of interest to
neuro-oncologists because it has potent antimitotic activity against
glioblastoma cells, associated with a rapid disassembly of micro-
tubules (Piepmeier et al, 1993). Estramustine-binding protein
(EMBP) is more predominant in glioma cells than in normal brain
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tissue (von-Shoultz et al, 1991a). Furthermore, EMP can cross the
blood-brain barrier (Bergenheim et al, 1993). One of the major
limitations to the effective treatment of malignant gliomas is the
propensity of these lesions to infiltrate into the surrounding brain
tissue. Degradation of the extracellular matrix is mediated by
tumour cell-secreted proteolytic enzymes (Pedersen et al, 1994),
such as matrix metalloproteinases (MMPs) (Nakano et al, 1995).
Several authors have demonstrated the importance of MMPs in
glioma cell invasion (Reict and Rucklidge, 1992; Abe et al, 1994)
and have elucidated the structure of the MMP gene family
(Birkedal-Hansen et al, 1993). However, to our knowledge, no
studies have focused on the modulation of MMP activity by anti-
microtubule agents such as EMP.
In the present experiments, we investigated the relationship
between MMP enzyme activity and invasiveness after disassembly
of the microtubules by EMP. We measured cell densities with a
quantitative analysis in the cell proliferation assay (Barna et al,
1990), which would be changed in each EMP group by the
cytotoxic effect ofEMP while the other assays were examined. The
enzyme activity was determined by a collagenolytic assay and
gelatin zymographic analysis (Nakano et al, 1995). Cell invasive-
ness was detected with ahaptoinvasion assay using Boiden's cham-
bers with Matrigel (Albini et al, 1987). The nomenclature for the
MMP follows the numbering system according to Nakano (1995).
MATERIALS AND METHODS
Cell preparation
Human glioblastoma cells, U87MG (American Type Culture
Collection, Rockville, MD, USA), were cultured in plastic flasks
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Figure 2 Transparent bands indicating the presence of an activated form of
MMP-2 (62 kDa), demonstrating a reduction in a dose-dependent manner
(Falcon, 150 cm2) with DME medium (Sigma, St Louis, MO,
USA) containing 10% heat-inactivated fetal calf serum (Biocell,
Carson, CA, USA) supplemented with 0.05% (w/v) L-glutamine,
100 jig ml-' gentacin and 200 IU ml-' penicillin (hereafter called
culture medium). The cells were maintained at 37°C in humidified
atmosphere containing 5% carbon dioxide. Culture medium was
exchanged twice a week. Upon reaching subconfluence, the cells
were detached from the flask with 0.05% trypsin/0.02% EDTA.
Before use, the cells were rinsed in phosphate-buffered saline
(PBS), centrifuged at 1000 r.p.m. for 10 min and the resulting
pellet was resuspended in fresh culture medium. This rinse after
the detachment procedure ensured that there would be no active
trypsin or antibiotics to affect the artificial basement membrane.
The cell density was determined with a haemocytometer.
Drug
Powdered estramustine phosphate sodium (Estracyt), (1,3,5(10)-
estratriene3,17bdiol3[bis (2chloroethyl) carbamate] 17disodium
salt, hydrate]; (molecular weight, 582.4); from Pharmacia,
Helsingborg, Sweden) (Figure 1) (EMP) was dissolved in distilled
water (10-2 mol 1-'). The drug solution was stored at 4'C. This
stock solution was then diluted in the culture medium immediately
before use.
Gelatin zymography for detection of MMP
Gelatin substrate zymograms were performed, as previously
described (Nakagawa et al, 1994). Gradient sodium dodecyl
sulphate (SDS) polyacrylamide slab gels (5-15%) were impreg-
nated with gelatin (1 mg ml-') (Sigma, MO, USA). Exponentially
growing cells (1.5 x 107 cells) were placed in a plastic flask
(75 cm2, Falcon) and allowed to attach to the bottom for 24 h in
cultured medium. After two rinses with PBS, the cells were
exposed to 0, 0.5, 1, 5 or 10 jiM EMP in 20 ml of serum-free
conditioned medium. After 24-h incubation at 37°C in humidified
atmosphere containing 5% carbon dioxide, the medium was
centrifuged at 10 000 g, and the supernatant was used for the
assay. The samples (the supematant) were not heated before
electrophoresis. An aliquot (45 p1) ofeach sample was mixed with
15 gl of sample buffer (0.25 M Tris, 8% SDS, 40% glycerol,
0.48 mg ml-' bromophenol blue). Gels were run at 20 mA at 4°C
for 5 h and then washed with 10 mM Tris buffer containing 2.5%
Triton X-l00. MMPs were activated by incubation for 24 h in a
buffer consisting of 50 mM Tris, 0.5 mm calcium chloride, and
10 mm zinc chloride. Gels were stained with Coomasie blue (1%),
and destained in 10% methanol, 5% acetic acid. Transparent bands
on the.background ofthe Coomasie blue-stained slab gels indicate
the presence of gelatinolytic enzymes with type IV collagenolytic
activity.
Type IV collagenolytic activity
We examined type IV collagenolytic activity, as previously
described (Abe et al, 1994). Briefly, a solution of [3H]proline type
IV collagen (10jiCi) (Sigma, MO, USA) in 200 ,ul of0.5 M acetic
acid, supplemented with 50 jig ascorbic acid in 10% FBS (Wako,
Japan) was placed in each well of a 6-well culture plate and left in
the laminar air flow hood at room temperature to dry out. Type IV
collagenolytic activity was measured as follows: 2 x 105 cells
suspended in 1 ml of 0, 0.5, 1.0, 5.0 or 10.0jiM EMP solution in
culture medium were seeded on the dried [3H]collagen film and
incubated at 37°C for 1, 3, 6, 12 or24 h. The incubation was termi-
nated by chilling the plates on ice, and 500 jl ofthe culture super-
natant were mixed with 250 pl of 10% trichloroacetic acid and
0.5% tannic acid. After centrifugation at 8000 g for 10 min, to
remove precipitate that contained undigested collagen and cells,
the 3H activity ofthe supernatant was measured by liquid scintilla-
tion (Beckman LS3801). The type IV collagenolytic activity ofthe
glioma cells was determined by subtracting the mean value of
preliminary experiments that were performed without cells
(210 dpm). The enzymatic activity at each dose of EMP was
estimated from the time curves using a single coefficient correla-
tion analysis (Cricket Graph ver. 1.3.1, Malvern, PA, USA).
Haptoinvasion assay
In vitro invasiveness was evaluated by the method of Albini
(1987), with slight modifications. The soluble extracellular matrix,
reconstituted basement membrane substance and Matrigel
(Collaborative Research, Lexington, MA, USA) were diluted to
achieve a final concentration of 1 mg ml-' in serum-free DME
medium. This was coated on transwell polycarbonate filter inserts
(100gl) to form a thin, continuous layer on top of the filter, and
allowed to gel for 30 min at 37°C in a humidified atmosphere of
5% carbon dioxide. The transwell chamber with the Matrigel was
dried at room temperature overnight. The lower surface of the
filter was coated with 100pl of fibronection (20jg ml-l) as a
chemoattractant, and was dried at room temperature overnight.
Before the addition of the cell suspension, excess medium was
removed from the upper compartment. Assays were carried out
using 24-well plates with transwell chambers containing polycar-
bonate filters with 8 jim pores (Costar, Cambridge, MA, USA).
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Figure 3 The enzymatic activity (lysis velocity) of type IV collagenases in
U87 MG glioma cells exposed to estramustine phosphate (EMP). 10AM
EMP, A, 29.973 d.p.m. h-1, R2 = 0.794; 5 gM EMP, A, 142.20 d.p.m. h-',
R2 = 0.984; 1 gM EMP, 0, 198.27 d.p.m. h-1, R2 = 0.989; 0.5gM EMP, *,
490.25 d.p.m. h-', R2 = 0.993; control, E, 558.09 d.p.m. h-', R2 = 0.997;
(R2 = correlation coefficiency). Error bars denote the standard error of
the mean
RESULTS
Gelatin zymography for the detection of MMPs
The zymogram (Figure 2) disclosed only an activated form of
MMP-2 (62 kDa) that diminished with increasing concentrations
of EMP. MMP-2 activity at 0.5 jM EMP was not significantly
lower than that for non-EMP treated cells.
Type IV collagenolytic activity
The enzymatic activity was expressed as the quantity of3H-labelled
type IV collagen solubilized into the medium per hour (Figure 3).
30 Approximately 2.5- to 21-fold lower rates of enzymatic activity
were suppressed by EMP in a concentration-dependent manner
(10 gM: 29.97 d.p.m. h-', R2 = 0.79 (R2 = correlation coefficiency),
5 gM: 142.20 d.p.m. h-1, R2 = 0.98, 1 gM: 198.3, R2 = 0.99). EMP
(0.5 gM) did not cause significant inhibition of type IV collagen
degradation in this assay compared with the control group (0.5 gM:
490.25 d.p.m. h-1, R2 = 0.99, control: 558.09 d.p.m. h-1, R2 = 0.99).
Haptoinvasion assay
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Figure 4 Number of U87 MG cells invading through the Matrigel and
micropore filter in the haptoinvasion assay. *P< 0.01 vs 0gM EMP;
**P< 0.005 vs 0gM EMP; ***P < 0.001 vs 0gM EMR Error bars denote the
standard error of the mean. 0, Control; 0, 0.5 JM EMP; O, 1 gM EMP; A,
5gM EMP; A, 10gM EMP
The upper chambers (6.5 mm in diameter) were filled with 250 pl
ofcell suspension (1 x 105 cells ml-) with different concentrations
of EMP diluted in serum-free culture medium (0, 0.5, 1, 5 or
10gM). Medium with the same EMP dilution (250 tl) was placed
in each of the lower chambers. The chambers were incubated at
37°C in a humidified atmosphere of5% carbon dioxide for 1, 3, 6,
12 or 24 h. After the incubation, the cells on the upper surface of
the micropore filter were removed by wiping with a cotton swab,
and cells on the lower surface were fixed with 95% ethanol and
stained with haematoxylin and eosin. The determination of
haptoinvasion was performed by counting the cells that had
migrated to the lower side ofthe filter, using a light microscope at
100 x magnification. Ten random fields were counted for each
assay. Assays were repeated twice.
For statistical analysis, differences between mean values were
tested using Student's t-test. Statistical significance was taken
as P < 0.01 (Statworks, version 1.2, Cricket Software,
Philadelphia, PA, USA).
No statistical significance was seen in the 0.5gM EMP exposure
group throughout the examination, whereas the 1-10gM EMP
groups revealed significant suppression of invasion from 6 to 24h,
compared with the control group, in a concentration-dependent
fashion [1 gM EMP (6 h, P < 0.01; 12 h, P < 0.01; 24h, P < 0.005),
5gMEMP (6h, P < 0.01; 12h, P < 0.005; 24h, P < 0.005), 10gM
EMP(6h, P <0.01; 12h, P <0.005; 24h,P <0.001)] (Figure4).
DISCUSSION
Estramustine phosphate and malignant glioma
EMP, an antimicrotubule agent, is a steroid-alkylating agent,
consisting of an oestradiol-170-phosphate conjugated to nor-HN2
through a carbamate ester linkage (Morage et al, 1992). This drug
has been used against advanced prostate carcinomas as an oral
agent. It was designed to allow direct delivery of the alkylating
agent to the cancer cell through binding of the hormonal moiety to
oestrogen receptors on cancer cells (Speicher et al, 1994). Activity
against glioblastoma has been reported recently (von-Schoultz
et al, 1988; 1989; 1990; 1991a,b; Piepmeier et al, 1993), although
glioblastomas rarely express oestrogen-binding receptors on their
cell membrane (von-Shoultz et al, 1990). EMP binds specifically to
estramustine binding protein (EMBP), which is found in greater
quantities in glioma tissue than in normal brain tissue (von-Shoultz
et al, 1991a). EMBP causes a partial disassembly of microtubules
(Bergenheim et al, 1994) and withdrawal of microtubules from the
cell periphery towards the perinuclear area, resulting in arrest ofthe
cell cycle in the G/M phase (Yoshida et al, 1994b). The distribution
ofEMBPmay contribute tothe selective cytotoxic effect ofEMP on
glioblastoma cells. The specific distribution of microtubule-associ-
ated proteins (MAP) in gliomas and normal brain and relationship
with EMBP has not yet been clarified. The disassembling ofmicro-
tubules increases the radiosensitivity of glioma cells (Ryu et al,
1994; Yoshidaetal, 1994b) andresults in aconcentration-dependent
alteration in cell size and shape within minutes (Piepmeier et al,
1993), as well as inhibiting proliferation and cell viability (Yoshida
et al, 1996). The aim ofthe current study was to provide additional
information about the mechanism of action of EMP. We examined
how the secretion ofMMPs is modulated by EMP.
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Invasion of gliomas and matrix metalloproteinases
The invasiveness of glioblastomas is an essential function to over-
come clinically as it is one of the key features that makes gliomas
resistant to surgical resection. Matrix metalloproteinases are known
to play acrucial role in the invasive nature ofanumberofneoplasms
(Birkedal-Hansen et al, 1993), including malignant gliomas (Reict
and Rucklidge, 1992). This family ofzinc-dependent endopeptidases
includes interstitial collagenases (MMP-l and -8), type IV colla-
genases/gelatinases (MMP-2 and -9), stromelysins (MMP-3 and -10)
and matrilysin (MMP-7) (Nakano et al, 1995). They are encoded by
separate genes, but share some protein sequence homology and
activation mechanisms (Birkedal-Hansen et al, 1993). Recent studies
have disclosed thattheproenzymes ofMMP-2 (72 kDa) andMMP-9
(92 kDa) are activated in the presence of zinc ions to their activated
forms, MMP-2 (62 kDa) and MMP-9 (83 kDa), in the extracellular
space(Birkedal-Hansen etal, 1993; Nakagawaetal, 1994; Nakano et
al, 1995). The molecular weight of the transparent band seen in the
zymograph in this study was 62 kDa, consistent with activated
MMP-2. MMP-2 and MMP-9 (type IV collagenases) are regarded
as key factors in various pathological conditions, involving tissue
remodelling and morphogenesis (Rao et al, 1993). Several authors
have analysed the activity of MMPs in human brain tumours,
compared with that in normal brain tissue (Nakagawa et al, 1994).
Cell invasiveness is positively correlated with the presence ofMMP-
2 or MMP-9. Nakano and colleagues (1995) have quantitated the
expression ofMMP mRNA in human glioma cells, and have shown
that U87MG cells predominantly express mRNA for MMP-2 by
Northern blotanalysis. This confirms thattheband seen in ourzymo-
graphic analysis (Figure 2) was MMP-2. The secretion of activated
MMP-2 was inhibited in a concentration-dependent manner in this
study. Whether secretion of MMP-9 or the other subtypes in the
MMP family would be altered by the exposure with EMP could not
be examined. Steams andcolleagues (1991) described that inhibition
of type IV collagenase secretion by estramustine was achieved on
DU 145a cells, a prostate carcinoma cell line. In the studies, he
stressed that the effect was not a result ofinhibition ofeither protein
synthesis or altered rate oftype IV collagenase turnover, but a result
ofpartial disruption of the microtubule networks by binding MAP-
IA as the principal target ofthe drug. Other authors have discussed
several factors that regulate the secretion of MMPs, such as tissue
inhibitors of MMPs (TIMP), urokinase-type plasminogen and
neural cell adhesion molecule (NCAM) (Mohanam et al, 1993).
Furthermore, one author (Nakano et al, 1995) examined the
transcriptional regulation of MMP and TIMP genes by tumour
promoters, growth factors and cytokines, such as TGF-P, EGF,
TNF-a, (IL)-1[, and IL-6. We are not aware of any studies on the
regulation ofMMPs by anti-cancer agents orby the microtubules.
In the initial stage oftumour angiogenesis, capillary endothelial
cells destroy the basement membrane surrounding intact capil-
laries and migrate through the. extracellular matrix toward the
source of the angiogenic stimulus. The induction of this endothe-
lial cell migration requires the presence of MMPs (Taylor et al,
1991). Vaithilingam has reported an increase in the activity of
general proteinases and type IV collagenases (MMP-2 and -9) in
the serum, associated with the growth of C6 rat glioma cells in a
spheroid implantation model (Vaithilingam et al, 1992).
Nakagawa and colleagues (1994) have shown that immunoreac-
tive MMP is found in the neovascuralized areas of brain tumours.
Thus, the regulation of MMPs in the extracellular matrix could be a
novel methodofinhibiting tumourangiogenesis. Wefirstdetermined
the secretion of activated MMP-2 by U87MG by a collagenolysis
assay. MMP-2 secretion was suppressed by EMP in a concentration-
dependent manner. Cell migration occurring in response to an
immobilized substrate, such as the extracellular matrix, is called
haptotaxis. Cell invasion through such a substrate is called hapto-
invasion (Djakiew et al, 1993). This haptoinvasion requires initial
cell motility, and secondary penetration through the substrate by the
digestion and secretion of proteolytic enzymes. Thus, the U87MG
cells, with reduced MMP-2 production secondary to EMP exposure,
inhibited the degradative capacity of reconstituent basement
membrane, Matrigel, consisting of collagen type IV (Janiak et al,
1994). Cell invasion mediatedby the degradation ofcollagen type IV
by MMP-2 represents just one ofthe mechanisms involved in base-
mentmembrane penetration. Anotherfactor which may contribute to
haptoinvasion is the alterations in cell shape, mediated by micro-
tubules, which are necessary to maintain cell motility (Rutberg and
Wallin, 1993; Yoshida et al, 1996). Despite the cytotoxic effect, our
previous report (Yoshida et al, 1996) showed that cell population
after exposure with 0 to 10 gM EMP did not change significantly
when the exposure time was within 24h. Hence, the present study
was performed with the same cell densities. Therefore, production of
MMP-2 for each cell must be suppressed in the series of assays, not
by the cytoreductive effect ofEMP.
The chemical components of Matrigel do not match those of
normal brain tissue (Paulus and Tonn, 1994). Collagen type IV,
however, is a major component of both normal brain structures
and of blood vessels (Santell et al, 1992). Therefore, the dimin-
ished collagenolysis and the decreased invasiveness in Matrigel
demonstrated in the present study may be highly implicative of
clinical activity ofEMP in the patients with malignant gliomas.
CONCLUSION
In conclusion, estramustine phosphate inhibits the secretion of
matrix metalloproteinases-2 and the invasiveness of human
glioblastoma cells in vitro. Primarily targeting MAP-lA protein
may cause partial disruption of microtubular networks that would
induce reduction ofMMP-2, not as a result ofaltered rate of MMP-
2 turnover (Steams et al, 1991). Loss of cell locomotion may
account for the inhibition of invasiveness. The invasive propensity
of glioblastomas may be dependent on (a) initial cell locomotion;
(b) the secretion of proteinases for remodelling the basement
membrane and neighbouring structures; and (c) the regrowth of the
tumour cell population after penetration through the adjacent struc-
tures. Thus, the inhibition and disruption of these processes must
inhibit glioma cell invasion. The importance of additional mecha-
nisms, such astranscriptional regulation ofMMPgenes and therele-
vance ofmicrotubule disassembly, remain to be established.
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